Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG)

Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved di...

Full description

Saved in:

Bibliographic Details
Published in:	Breast cancer research and treatment Vol. 112; no. 3; pp. 557 - 563
Main Authors:	Kahán, Zsuzsanna, Spanik, Stanislav, Wagnerova, Maria, Skacel, Tomas, Planko, Barbara, Fitzthum, Elisabeth, Lindner, Elisabeth, Soldatenkova, Victoria, Zielinski, Christoph C., Brodowicz, Thomas
Format:	Journal Article
Language:	English
Published:	Boston Springer US 01-12-2008 Springer Springer Nature B.V
Subjects:	Adolescent Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - therapy Cancer research Cancer therapies Chemotherapy Chemotherapy, Adjuvant - methods Clinical Trial Clinical trials Cyclophosphamide - therapeutic use Dose-Response Relationship, Drug Drug dosages Epirubicin - therapeutic use Female Filgrastim Fluorouracil - therapeutic use Granulocyte Colony-Stimulating Factor - administration & dosage Granulocyte Colony-Stimulating Factor - metabolism Humans Medical Oncology - methods Medicine Medicine & Public Health Middle Aged Oncology Polyethylene Glycols Recombinant Proteins Side effects Treatment Outcome Dose densification Chemotherapy Cyclophosphamide Pegfilgrastim Granulocyte colony-stimulating factor Breast cancer Epirubicin Fluorouracil
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!